A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

Back to Search
Print
Bookmark Trial

NCT00801515

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Montreal, Quebec, H3G 1A4, Canada
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
HIV
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients having completed study A4001029 in Canada and still deriving clinical benefit.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- None

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

HIVEffects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
NCT00634959
  1. Birmingham, Alabama
  2. Boston, Massachusetts
  3. Frankfurt,
  4. Hamburg,
  5. Koeln,
  6. London,
  7. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HIVA Compassionate Access Protocol For Those Patients Who Have Completed A4001029
NCT00801515
  1. Montreal, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HIVMaraviroc Switch Collaborative Study
NCT01384682
  1. Buenos Aires, Ciudad de Buenos Aires
  2. Buenos Aires, Ciudad de Buenos Aires
  3. Buenos Aires, Ciudad de Buenos Aires
  4. El Palomar, Provincia de Buenos Aires
  5. Isidro Casanova, Provincia de Buenos Aires
  6. Rosario, Provincia de Santa Fe
  7. Buenos Aires,
  8. Cordoba,
  9. Sydney, New South Wales
  10. Sydney, New South Wales
  11. Sydney, New South Wales
  12. Sydney, New South Wales
  13. Bisbane, Queensland
  14. Brisbane, Queensland
  15. Nambour, Queensland
  16. Adelaide, South Australia
  17. Melbourne, Victoria
  18. Melbourne, Victoria
  19. Calgary, Alberta
  20. Toronto, Ontario
  21. Toronto, Ontario
  22. Montreal, Quebec
  23. Santiago, Santiago RM
  24. Orleans,
  25. Frankfurt, Frankfurt am Main
  26. Berlin,
  27. Berlin,
  28. Bonn,
  29. Cologne,
  30. Düsseldorf,
  31. Hannover,
  32. Dublin,
  33. Nagoya,
  34. Guadalajara, Jalisco
  35. Leon,
  36. Mexico City,
  37. Warsaw,
  38. Badalona, Catalonia
  39. Barcelona, Catalonia
  40. Barcelona, Catalonia
  41. Madrid,
  42. Madrid,
  43. Malaga,
  44. Seville,
  45. Valencia,
  46. Bangkok,
  47. Edinburgh, Lothian
  48. Brighton, Sussex
  49. Coventry, Warwickshire
  50. London,
  51. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HIVA Phase 2 Study Of PF-00232798 In HIV Positive Patients
NCT00495677
  1. Frankfurt am Main,
  2. Koeln,
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
Brief Summary This is a compassionate study to provide continued access to maraviroc for only those subjects completing study A4001029 who are showing clinical benefit. Assessments of safety and tolerability of maraviroc when added to OBT will be continued.
Detailed Description Not Provided
Study Type Expanded Access
Intervention Drug: Maraviroc
150 mg twice per day
Other Name: Celsentri
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status No longer available
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Canada
Removed Location Countries  
 
Administrative Information
NCT Number NCT00801515
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor ViiV Healthcare
Collaborators Pfizer
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account ViiV Healthcare
Verification Date July 2011